Recent News

• 09.10.2025 - Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update
• 09.02.2025 - Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
• 08.12.2025 - Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
• 08.07.2025 - Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.04.2025 - Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

Recent Filings

• 09.10.2025 - 8-K Current report
• 09.09.2025 - DEF 14A Other definitive proxy statements
• 09.09.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 08.28.2025 - PRE 14A Other preliminary proxy statements
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - 8-K Current report
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - 8-K Current report
• 08.04.2025 - 8-K Current report